In a February 19th release, Elanco Animal Health (ELAN) reported on Q4 and FY 2019 ending December 31st 2019. For the quarter, Elanco lost $9.5 million on revenue of $787 million with a negative EPS of $0.03. For the comparable fourth quarter of fiscal 2018, Elanco posted a profit of $16.4 million on revenue of $799.3 million. This quarter included an income tax benefit of $18.6 million.
For fiscal 2019, Elanco generated a net profit of $67.9 million on revenue of $3.071 billion with a $0.18 EPS. Comparable figures for fiscal 2018 were a net profit of $86.5 million on revenue of 3.067 billion with an EPS of $0.28
For the quarter, companion animal sales represented 34 percent and food species, 64 percent of revenue. In providing guidance for FY 2020, the company projected revenue of between $3.05 and $3.11 billion with an adjusted EPS range of $1.09 to $1.16 or a diluted EPS of $0.04 to $0.16.
In commenting on results the company recorded a decline in sales of Paylene® their propriety brand of ractopamine and Rumensin® supplement for cattle. Elanco Animal Health noted an improvement in volume of poultry vaccines sold.